A large-scale screen of tuberculosis proteins has revealed several possible antigens that could be developed as a new vaccine for TB, the world's deadliest infectious disease.

CAMBRIDGE, MA / ACCESS Newswire / November 3, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, the Company’s investigational ...

A large-scale screen of tuberculosis proteins has revealed several possible antigens that could be developed as a new vaccine for TB, the world's ...

Cardiovascular disease continues to be the leading cause of death worldwide. But advances in heart-failure therapeutics have ...

The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients by boosting their immune systems to help fight tumors. Research reported recently in the journal Nature ...

The decades-long quest to harness the power of messenger RNA to enhance cancer treatment has focused primarily on its value ...

Cardiologists need to know how to recognize and manage the cardiac effects that can arise from SARS-CoV-2 infections or COVID ...

It is evolutionarily certain that we will have more outbreaks, more pandemics, and frankly, they could be significantly worse than Covid,” says global health expert Seth Berkley.

Scientists have developed an experimental mRNA vaccine that, when combined with existing immunotherapy drugs, could 'teach' ...

Among mRNA tech, vaccines have been the primary target of the federal ... to protein-construction sites where the complex ...

The observation that mRNA vaccines can sensitize tumors to immunotherapy has researchers eager to test how mRNA’s ability to activate the immune system could be harnessed in oncology.